| [1] | World Health Organization (2004) Equitable access to essential medicines: A framework for collective action. Geneva: World Health Organization. Available: http://whqlibdoc.who.int/hq/2004/WHO_EDM？_2004.4.pdf. Accessed 6 March 2006.
|
| [2] | Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, et al. (2002) Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet 359: 2188–2194.
|
| [3] | Quick JD (2003) Essential medicines twenty-five years on: Closing the access gap. Health Policy Plan 18: 1–3.
|
| [4] | Cohen WM, Nelson RR, Walsh JP (2002) Links and impacts: The influence of public research on industrial R&D. Manage Sci 48: 1–23.
|
| [5] | Moses H, Dorsey ER, Matheson DH, Their SO (2005) Financial anatomy of biomedical research. JAMA 294: 1333–1342.
|
| [6] | Kapczynski A, Crone ET, Merson M (2003) Global health and university patents. Science 301: 1629.
|
| [7] | World Health Organization (2003) Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public-health approach. Geneva: World Health Organization. Available: http://www.who.int/hiv/pub/prev_care/en/？arvrevision2003en.pdf. Accessed 6 March 2006.
|
| [8] | Emory University (2005 18 July) Press release. Atlanta (Georgia): Emory University. Available: http://www.news.emory.edu/Releases/emtri. Accessed 6 March 2006.
|
| [9] | Cohen R (2006) Interview. Atlanta (Georgia): Curbside Consult. Available: http://www.hstatweb.org/curbsideconsult/？Episodes/CurbsideConsultEpisode1.mp3. Accessed 6 March 2006.
|
| [10] | Humanitarian Licensing Working Group Science and Intellectual Property in the Public Interest Program American Academy of Arts and Sciences (2005) Exploring a humanitarian use exemption to intellectual property protections. Washington (D. C.): SIPPI Humanitarian Use Exemption Working Group. Available: http://sippi.aaas.org/SIPPI%20Humanitari？an%20Use%20Report%20-%20July%202004.doc. Accessed 13 March 2006.
|
| [11] | Universities Allied for Essential Medicines (2005) Statement on university policies for health-related innovations. New Haven (Connecticut): Yale University. Available: http://www.essentialmedicine.org/Oct2005？PolicyStatement.pdf. Accessed 6 March 2006.
|
| [12] | Chokshi DA (2005) Universities should foster neglected-disease work. Nature 435: 143.
|
| [13] | Kapczynski A, Chaifetz S, Katz Z, Benkler Y (2005) Addressing global health inequities: An open licensing approach for university innovations. Berkeley Technol Law J 20: 1031–1114.
|
| [14] | Outterson K (2005) Pharmaceutical arbitrage: Balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics 5: 193–286.
|
| [15] | World Trade Organization General Council (2003) Implementation of paragraph 6 of the Doha Declaration on the TRIPS agreement and public health. Geneva: World Trade Organization. Available: http://www.wto.org/English/tratop_e/trip？s_e/implem_para6_e.htm. Accessed 6 March 2006.
|
| [16] | Association of University Technology Managers (2002) AUTM licensing survey: FY 2001. Northbrook (Illinois): Association of University Technology Managers. Available: http://www.asm.org/ASM/files/LEFTMARGINH？EADERLIST/DOWNLOADFILENAME/0000001066/au？tmsummarypublicversion.pdf. Accessed 6 March 2006.
|
| [17] | Widdus R, White K (2004) Combating diseases associated with poverty (abridged version). Geneva: World Health Organization. >Available: http://www.ippph.org/index.cfm?page=/ipp？ph/publications&thechoice=retrieve&docno？=98. Accessed 6 March 2006.
|
| [18] | Office of Intellectual Property and Industry Research Alliances (2005) Socially responsible licensing at UC-Berkeley. Berkeley (California): University of California Berkeley. Available: http://ipira.berkeley.edu/docs/sociallyr？esponsible10-05.pdf. Accessed 6 March 2006.
|
